肾复康胶囊联合他克莫司治疗膜性肾病的临床研究  

Clinical study on Shenfukang Capsules combined with tacrolimus in treatment of membranous nephropathy

作　　者：刘俊英[1] 贾国强[1] 陈豫闽[1] LIU Jun-ying;JIA Guo-qiang;CHEN Yu-min(Department of Nephrology,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471003,China)

机构地区：[1]河南科技大学第一附属医院肾内科,河南洛阳471003

出　　处：《现代药物与临床》2020年第6期1186-1189,共4页Drugs & Clinic

摘　　要：目的研究肾复康胶囊联合他克莫司胶囊治疗膜性肾病的临床疗效。方法选取2017年10月—2019年10月在河南科技大学第一附属医院治疗的84例膜性肾病患者,所有患者随机分为对照组和治疗组,每组各42例。对照组餐前1 h口服他克莫司胶囊,0.05mg/(kg·d),2次/d;治疗组在对照组基础上口服肾复康胶囊,4粒/次,3次/d。两组患者持续治疗4周。观察两组的临床疗效,比较两组的肾功能指标、炎性因子水平。结果治疗后,对照组和治疗组的总有效率分别为80.95%、95.24%,两组比较差异有统计学意义(P<0.05)。治疗后,两组患者24 h尿蛋白(24 h UTP)、血肌酐(Scr)和血尿素氮(BUN)水平显著降低(P<0.05);并且治疗组肾功能指标明显低于对照组(P<0.05)。治疗后,两组患者白细胞介素-4(IL-4)、白细胞介素-10(IL-10)水平均显著降低(P<0.05);且治疗组血清炎性因子水平显著低于对照组(P<0.05)。结论肾复康胶囊联合他克莫司胶囊治疗膜性肾病具有较好的治疗效果,能够改善患者肾功能,降低血清炎性因子水平,安全性较高,值得在临床上推广应用。Objective To study the clinical effect of Shenfukang Capsules combined with Tacrolimus Capsules in treatment of membranous nephropathy. Methods Patients(84 cases) with membranous nephropathy in the First Affiliated Hospital of Henan University of Science and Technology from October 2017 to October 2019 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were po administered with Tacrolimus Capsules at 1 h before meals, 0.05 mg/(kg·d), twice daily. Patients in the treatment group were po administered with Shenfukang Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and renal function and inflammatory factors in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.95% and 95.24%, respectively, and there was difference between two groups(P < 0.05). After treatment, the levels of 24 h UTP, Scr and BUN in two groups were significantly decreased(P < 0.05). And the renal function indexes in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the levels of IL-4 and IL-10 in two groups were significantly decreased(P < 0.05). And the inflammatory factors in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Shenfukang Capsules combined with Tacrolimus Capsules has clinical curative effect in treatment of membranous nephropathy, can improve the renal function of patients, reduce the serum level of inflammatory factors, with good safety, which is worthy of clinical application.

关 键 词：肾复康胶囊 他克莫司胶囊 膜性肾病 肾功能 炎性因子 

分 类 号：R976[医药卫生—药品]